Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC).
Kroep
J R
JR
Department of Med. Oncology, University Hospital VU, Amsterdam, The Netherlands.
van Moorsel
C J
CJ
Veerman
G
G
Voorn
D A
DA
Schultz
R M
RM
Worzalla
J F
JF
Tanzer
L R
LR
Merriman
R L
RL
Pinedo
H M
HM
Peters
G J
GJ
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000201:enzymology*; D003564:Cytidine Deaminase; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003842:Deoxycytidine Kinase / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000201:enzymology*; D051379:Mice; D009700:Nucleoside Deaminases / Q000378:metabolism*; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000201:enzymology*; D013937:Thymidine Kinase / Q000378:metabolism*; D014183:Transplantation, Heterologous; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; C105339:thymidine kinase 2; D013937:Thymidine Kinase; D003842:Deoxycytidine Kinase; D009700:Nucleoside Deaminases; D003564:Cytidine Deaminase; C011530:deoxycytidine deaminase; D000093542:Gemcitabine